Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.
A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.
Application Note

A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.

In this application note, we evaluate the Pin-point™ base editing platform as a tool for precise, safe and efficient engineering of hematopoietic stem and progenitor cells (HSPCs) by editing two therapeutically relevant targets known to reactivate expression of fetal hemoglobin.

You will learn how to:

  • Achieve efficient, high-purity base editing of therapeutic targets
  • Upregulate fetal hemoglobin while preserving cell differentiation
  • Multiplexed editing without compromising efficiency or cell growth
  • Unlock new possibilities for gene therapy

The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
 

Download Resource

A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.

Download Application Note
Revvity Logo

©2026 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.